An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma

NCT07344818 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

R/R Aggressive B-cell Lymphoma

Interventions

BIOLOGICAL: CAR-T cell therapy

Sponsor

Peking University People's Hospital

Collaborators

[object Object]